{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:58:30Z","timestamp":1793761110255,"version":"4.6.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35DE030045"],"award-info":[{"award-number":["R35DE030045"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.pharmthera.2024.108668","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T02:24:25Z","timestamp":1716344665000},"page":"108668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain"],"prefix":"10.1016","volume":"259","author":[{"given":"Ana","family":"Bagues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishraq","family":"Alshanqiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Kyo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 4","key":"10.1016\/j.pharmthera.2024.108668_bb0005","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1113\/jphysiol.2012.242131","article-title":"Transsynaptic inhibition of spinal transmission by A2 botulinum toxin","volume":"591","author":"Akaike","year":"2013","journal-title":"The Journal of Physiology"},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108668_bb0010","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","article-title":"Long-distance retrograde effects of botulinum neurotoxin a","volume":"28","author":"Antonucci","year":"2008","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108668_bb0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/AJP.0b013e31827a72d2","article-title":"Botulinum toxin a in Postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial","volume":"29","author":"Apalla","year":"2013","journal-title":"The Clinical Journal of Pain"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107743","article-title":"Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain","volume":"220","author":"Arora","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108668_bb0025","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/j.pain.0000000000002529","article-title":"Capsaicin-induced depolymerization of axonal microtubules mediates analgesia for trigeminal neuropathic pain","volume":"163","author":"Arora","year":"2022","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108668_bb0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","article-title":"Safety and efficacy of repeated injections of botulinum toxin a in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial","volume":"15","author":"Attal","year":"2016","journal-title":"The Lancet Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pbb.2009.08.012","article-title":"Central origin of the antinociceptive action of botulinum toxin type a","volume":"94","author":"Bach-Rojecky","year":"2009","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00702-004-0265-1","article-title":"Botulinum toxin type a in experimental neuropathic pain","volume":"112","author":"Bach-Rojecky","year":"2005","journal-title":"Journal of Neural Transmission"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2024.108668_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2010.01.020","article-title":"Botulinum toxin type a reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection","volume":"633","author":"Bach-Rojecky","year":"2010","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2008.12.007","article-title":"CGRP receptors in the control of pain and inflammation","volume":"9","author":"Benemei","year":"2009","journal-title":"Current Opinion in Pharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108668_bb0055","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1524-4725.1998.tb04098.x","article-title":"Treatment of hyperfunctional lines of the face with botulinum toxin a","volume":"24","author":"Binder","year":"1998","journal-title":"Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108668_bb0060","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.semcdb.2006.10.008","article-title":"Glutamate receptors and pain","volume":"17","author":"Bleakman","year":"2006","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3344\/kjp.2022.35.4.391","article-title":"The role of botulinum toxin type a related axon transport in neuropathic pain induced by chronic constriction injury","volume":"35","author":"Bu","year":"2022","journal-title":"The Korean Journal of Pain"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108668_bb0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","article-title":"The action of botulinum toxin on the neuro-muscular junction","volume":"109","author":"Burgen","year":"1949","journal-title":"The Journal of Physiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108668_bb0075","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of OnabotulinumtoxinA in chronic migraine: A narrative review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/head.12250","article-title":"An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine","volume":"54","author":"Cady","year":"2014","journal-title":"Headache"},{"issue":"48","key":"10.1016\/j.pharmthera.2024.108668_bb0085","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1523\/JNEUROSCI.0294-18.2018","article-title":"Transynaptic action of botulinum neurotoxin type a at central cholinergic boutons","volume":"38","author":"Caleo","year":"2018","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108668_bb0090","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/WNR.0000000000000779","article-title":"Long-term anti-itch effect of botulinum neurotoxin a is associated with downregulation of TRPV1 and TRPA1 in the dorsal root ganglia in mice","volume":"28","author":"Cao","year":"2017","journal-title":"Neuroreport"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108668_bb0095","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Cernuda-Moroll\u00f3n","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0100","article-title":"Efficacy and safety of botulinum toxin a and pulsed radiofrequency on postherpetic neuralgia: A randomized clinical trial","volume":"2022","author":"Chen","year":"2022","journal-title":"Contrast Media & Molecular Imaging"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108668_bb0105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/toxins4100913","article-title":"Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments","volume":"4","author":"Chen","year":"2012","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-021-01254-2","article-title":"Unilateral facial injection of botulinum neurotoxin a attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice","volume":"22","author":"Chen","year":"2021","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1742-2094-11-98","article-title":"Neuroinflammation and M2 microglia: The good, the bad, and the inflamed","volume":"11","author":"Cherry","year":"2014","journal-title":"Journal of Neuroinflammation"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108668_bb0120","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.jpain.2022.08.004","article-title":"Cellular mechanisms mediating the Antinociceptive effect of botulinum toxin a in a rodent model of trigeminal irritation by a foreign body","volume":"23","author":"Cho","year":"2022","journal-title":"The Journal of Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdermsci.2018.12.004","article-title":"Botulinum toxin blocks mast cells and prevents rosacea like inflammation","volume":"93","author":"Choi","year":"2019","journal-title":"Journal of Dermatological Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/toxins13010058","article-title":"Botulinum toxin: An update on pharmacology and newer products in development","volume":"13","author":"Choudhury","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/1744806920914204","article-title":"Peripheral glutamate receptor and transient receptor potential channel mechanisms of craniofacial muscle pain","volume":"16","author":"Chung","year":"2020","journal-title":"Molecular Pain"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2024.108668_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin a reduces formalin-induced pain","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108668_bb0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/toxins11060359","article-title":"OnabotulinumtoxinA reduces temporal pain processing at spinal level in patients with lower limb spasticity","volume":"11","author":"De Icco","year":"2019","journal-title":"Toxins"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108668_bb0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00702-013-1150-6","article-title":"Association of antinociceptive action of botulinum toxin type a with GABA-A receptor","volume":"121","author":"Drinovac","year":"2014","journal-title":"Journal of Neural Transmission (Vienna, Austria: 1996)"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuropharm.2013.02.011","article-title":"Involvement of \u03bc-opioid receptors in antinociceptive action of botulinum toxin type a","volume":"70","author":"Drinovac","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type a: Implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache: The Journal of Head and Face Pain"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108668_bb0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies\u2014Successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0170","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.toxicon.2017.05.001","article-title":"Botulinum toxin type a reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain","volume":"133","author":"Fan","year":"2017","journal-title":"Toxicon: Official Journal of the International Society on Toxinology"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2024.108668_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2009.06.047","article-title":"Different antinociceptive effects of botulinum toxin type a in inflammatory and peripheral polyneuropathic rat models","volume":"617","author":"Favre-Guilmard","year":"2009","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108668_bb0180","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ejp.995","article-title":"Bilateral analgesic effects of abobotulinumtoxinA (Dysport \u00ae) following unilateral administration in the rat","volume":"21","author":"Favre-Guilmard","year":"2017","journal-title":"European Journal of Pain"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108668_bb0185","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ejp.995","article-title":"Bilateral analgesic effects of abobotulinumtoxinA (Dysport \u00ae) following unilateral administration in the rat","volume":"21","author":"Favre-Guilmard","year":"2017","journal-title":"European Journal of Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029803","article-title":"Central action of peripherally applied botulinum toxin type a on pain and dural protein extravasation in rat model of trigeminal neuropathy","volume":"7","author":"Filipovi\u0107","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0195","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"The Lancet. Neurology"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108668_bb0200","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/brain\/awab461","article-title":"OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients","volume":"145","author":"Gfrerer","year":"2022","journal-title":"Brain: A Journal of Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0205","first-page":"106","article-title":"The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy","volume":"19","author":"Ghasemi","year":"2014","journal-title":"Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0210","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuron.2019.01.012","article-title":"A mast-cell-specific receptor mediates neurogenic inflammation and pain","volume":"101","author":"Green","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13578-020-00405-3","article-title":"Botulinum toxin type a promotes microglial M2 polarization and suppresses chronic constriction injury-induced neuropathic pain through the P2X7 receptor","volume":"10","author":"Gui","year":"2020","journal-title":"Cell & Bioscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00500611","article-title":"125I-labeled neurotoxin from clostridium botulinum a: Preparation, binding to synaptosomes and ascent to the spinal cord","volume":"281","author":"Habermann","year":"1974","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0225","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.24605","article-title":"Botulinum toxin type a for neuropathic pain in patients with spinal cord injury","volume":"79","author":"Han","year":"2016","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0230","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jocd.15962","article-title":"Treating rosacea with botulism toxin: Protocol for a systematic review and meta-analysis","volume":"23","author":"He","year":"2024","journal-title":"Journal of Cosmetic Dermatology"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0235","doi-asserted-by":"crossref","DOI":"10.1007\/s11064-023-03893-0","article-title":"Analgesic effect of Perineural injection of BoNT\/a on neuropathic pain induced by chronic constriction injury of sciatic nerve in rats","author":"He","year":"2023","journal-title":"Neurochemical Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/toxins13020155","article-title":"The central effects of botulinum toxin in dystonia and spasticity","volume":"13","author":"Hok","year":"2021","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0245","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/23328940.2022.2075218","article-title":"Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief","volume":"10","author":"Iannone","year":"2023","journal-title":"Temperature (Austin, Tex.)"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108668_bb0250","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3390\/antiox11122361","article-title":"A systematic review and meta-analysis on the role of nutraceuticals in the management of neuropathic pain in in vivo studies","volume":"11","author":"Ilari","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114309","article-title":"Nociceptive signaling mediated by P2X3, P2X4 and P2X7 receptors","volume":"187","author":"Inoue","year":"2021","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0260","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neulet.2004.02.043","article-title":"Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumatic neuropathy model of the rat","volume":"360","author":"Jang","year":"2004","journal-title":"Neuroscience Letters"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0270","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/mus.27153","article-title":"Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache","volume":"63","author":"Kang","year":"2021","journal-title":"Muscle & Nerve"},{"issue":"31","key":"10.1016\/j.pharmthera.2024.108668_bb0275","first-page":"E6297","article-title":"Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain","volume":"114","author":"Kato","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0280","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.neuron.2013.12.011","article-title":"Central terminal sensitization of TRPV1 by descending serotonergic facilitation modulates chronic pain","volume":"81","author":"Kim","year":"2014","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0285","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.neuroscience.2009.01.066","article-title":"Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction","volume":"159","author":"Kitamura","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0290","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fneur.2014.00098","article-title":"Spinal central effects of peripherally applied botulinum neurotoxin a in comparison between its subtypes A1 and A2","volume":"5","author":"Koizumi","year":"2014","journal-title":"Frontiers in Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neures.2007.03.004","article-title":"Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat","volume":"58","author":"Lee","year":"2007","journal-title":"Neuroscience Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108668_bb0300","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201631","article-title":"New botulinum neurotoxin constructs for treatment of chronic pain","volume":"6","author":"Leese","year":"2023","journal-title":"Life Science Alliance"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0305","article-title":"Anti-inflammatory effects of BoNT\/a against complete Freund\u2019s adjuvant-induced arthritis pain in rats: Transcriptome analysis","volume":"12","author":"Li","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0310","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/ALN.0000000000000809","article-title":"Neuropathic allodynia involves spinal Neurexin-1\u03b2-dependent Neuroligin-1\/postsynaptic Density-95\/NR2B Cascade in rats","volume":"123","author":"Lin","year":"2015","journal-title":"Anesthesiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108668_bb0315","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1097\/j.pain.0000000000000366","article-title":"Wnt\/Ryk signaling contributes to neuropathic pain by regulating sensory neuron excitability and spinal synaptic plasticity in rats","volume":"156","author":"Liu","year":"2015","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108668_bb0320","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/toxins13110751","article-title":"Botulinum neurotoxins in central nervous system: An overview from animal models to human therapy","volume":"13","author":"Luvisetto","year":"2021","journal-title":"Toxins"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108668_bb0325","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/toxins14100704","article-title":"Botulinum neurotoxins beyond neurons: Interplay with glial cells","volume":"14","author":"Luvisetto","year":"2022","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2006.12.004","article-title":"Anti-allodynic efficacy of botulinum neurotoxin a in a model of neuropathic pain","volume":"145","author":"Luvisetto","year":"2007","journal-title":"Neuroscience"},{"issue":"450","key":"10.1016\/j.pharmthera.2024.108668_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7384","article-title":"Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice","volume":"10","author":"Maiar\u00f9","year":"2018","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2024.01.331","article-title":"Substance P-botulinum mediates long-term silencing of pain pathways that can be re-instated with a second injection of the construct in mice","author":"Maiar\u00f9","year":"2024","journal-title":"Journal of Pain"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108668_bb0345","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/j.pain.0000000000000478","article-title":"Nonparalytic botulinum molecules for the control of pain","volume":"157","author":"Mangione","year":"2016","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0350","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuroscience.2010.08.067","article-title":"Botulinum neurotoxin type a counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models","volume":"171","author":"Marinelli","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0355","doi-asserted-by":"crossref","first-page":"12529","DOI":"10.1038\/ncomms12529","article-title":"Dorsal horn neurons release extracellular ATP in a VNUT-dependent manner that underlies neuropathic pain","volume":"7","author":"Masuda","year":"2016","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0360","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bph.14846","article-title":"Evidence for central antispastic effect of botulinum toxin type a","volume":"177","author":"Matak","year":"2020","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0365","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","article-title":"Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin a","volume":"186","author":"Matak","year":"2011","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0370","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuint.2012.05.001","article-title":"Botulinum toxin\u2019s axonal transport from periphery to the spinal cord","volume":"61","author":"Matak","year":"2012","journal-title":"Neurochemistry International"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108668_bb0375","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.pain.2014.04.027","article-title":"Botulinum toxin type a selectivity for certain types of pain is associated with capsaicin-sensitive neurons","volume":"155","author":"Matak","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0380","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2017.06.040","article-title":"Involvement of substance P in the antinociceptive effect of botulinum toxin type a: Evidence from knockout mice","volume":"358","author":"Matak","year":"2017","journal-title":"Neuroscience"},{"issue":"15","key":"10.1016\/j.pharmthera.2024.108668_bb0385","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","article-title":"Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential","volume":"29","author":"Meng","year":"2009","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0390","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.neuroscience.2010.11.040","article-title":"The effect of botulinum neurotoxin a on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord","volume":"175","author":"Mika","year":"2011","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0395","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221141683","article-title":"OnabotulinumtoxinA effects on trigeminal nociceptors","volume":"43","author":"Moore","year":"2023","journal-title":"Cephalalgia: An International Journal of Headache"},{"issue":"584","key":"10.1016\/j.pharmthera.2024.108668_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay9056","article-title":"Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice","volume":"13","author":"Moreno","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108668_bb0405","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1097\/j.pain.0000000000001951","article-title":"Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific Nav1.7 regulation in the pathogenesis of chronic neuropathic pain","volume":"161","author":"Moutal","year":"2020","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108668_bb0410","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.pain.2013.07.041","article-title":"Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type a","volume":"154","author":"Mustafa","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0415","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.expneurol.2013.09.011","article-title":"Dynamic genotype-selective \u201cphenotypic switching\u201d of CGRP expression contributes to differential neuropathic pain phenotype","volume":"250","author":"Nitzan-Luques","year":"2013","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0420","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2018.06.016","article-title":"A SNAP-25 cleaving chimera of botulinum neurotoxin \/a and \/E prevents TNF\u03b1-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons","volume":"138","author":"Nugent","year":"2018","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108668_bb0425","first-page":"7791","article-title":"Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase","volume":"172","author":"Owen","year":"2004","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0430","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/0962935029000050","article-title":"Neutrophils and the calcium-binding protein MRP-14 mediate carrageenan-induced antinociception in mice","volume":"11","author":"Pagano","year":"2002","journal-title":"Mediators of Inflammation"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0435","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bju.13163","article-title":"Retrograde transport of radiolabelled botulinum neurotoxin type a to the CNS after intradetrusor injection in rats","volume":"117","author":"Papagiannopoulou","year":"2016","journal-title":"BJU International"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108668_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/toxins7114519","article-title":"Current status and future directions of botulinum neurotoxins for targeting pain processing","volume":"7","author":"Pellett","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0445","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1590\/0004-282x20160067","article-title":"Botulinum neurotoxin type-a when utilized in animals with trigeminal sensitization induced a antinociceptive effect","volume":"74","author":"Piovesan","year":"2016","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0450","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3390\/toxins2040683","article-title":"Bacterial toxins and the nervous system: Neurotoxins and multipotential toxins interacting with neuronal cells","volume":"2","author":"Popoff","year":"2010","journal-title":"Toxins"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0455","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","article-title":"Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain","volume":"64","author":"Ranoux","year":"2008","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxins13010001","article-title":"Engineering botulinum neurotoxins for enhanced therapeutic applications and vaccine development","volume":"13","author":"Rasetti-Escargueil","year":"2020","journal-title":"Toxins"},{"issue":"44","key":"10.1016\/j.pharmthera.2024.108668_bb0465","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1523\/JNEUROSCI.2618-11.2011","article-title":"Evidence for anterograde transport and transcytosis of botulinum Neurotoxin A (BoNT\/A)","volume":"31","author":"Restani","year":"2011","journal-title":"Journal of Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0470","first-page":"99","article-title":"The effects of botulinum toxin type a injection on pain symptoms, quality of life, and sleep quality of patients with diabetic neuropathy: A randomized double-blind clinical trial","volume":"18","author":"Salehi","year":"2019","journal-title":"Iranian Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0475","series-title":"StatPearls","article-title":"Physiology, Acetylcholine","author":"Sam","year":"2023"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0480","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3928\/0191-3913-19800101-06","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"17","author":"Scott","year":"1980","journal-title":"Journal of Pediatric Ophthalmology and Strabismus"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0485","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1129-2377-14-92","article-title":"Botulinum toxin-type a: Could it be an effective treatment option in intractable trigeminal neuralgia?","volume":"14","author":"Shehata","year":"2013","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2023.102346","article-title":"Intrathecal administration of botulinum toxin type a antagonizes neuropathic pain by countering increased vesicular nucleotide transporter expression in the spinal cord of chronic constriction injury of the sciatic nerve rats","volume":"100","author":"Shi","year":"2023","journal-title":"Neuropeptides"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108668_bb0495","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/j.pain.0000000000001973","article-title":"Quantitative differences in neuronal subpopulations between mouse and human dorsal root ganglia demonstrated with RNAscope in situ hybridization","volume":"161","author":"Shiers","year":"2020","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0500","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nbd.2012.07.010","article-title":"Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-a","volume":"48","author":"Shimizu","year":"2012","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.691396","article-title":"Orofacial neuropathic pain-basic research and their clinical relevancies","volume":"14","author":"Shinoda","year":"2021","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0510","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2020_351","article-title":"Novel native and engineered botulinum neurotoxins","volume":"263","author":"Steward","year":"2021","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108668_bb0515","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.dsx.2020.09.019","article-title":"The effect of intradermal botulinum toxin a injections on painful diabetic polyneuropathy","volume":"14","author":"Taheri","year":"2020","journal-title":"Diabetes and Metabolic Syndrome: Clinical Research and Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0520","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/ijms21010262","article-title":"New engineered-botulinum toxins inhibit the release of pain-related mediators","volume":"21","author":"Tang","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108668_bb0525","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0041-0101(03)00196-X","article-title":"Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: Time course of tissue distribution","volume":"42","author":"Tang-Liu","year":"2003","journal-title":"Toxicon: Official Journal of the International Society on Toxinology"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108668_bb0530","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1254\/jphs.11121FP","article-title":"Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats","volume":"117","author":"Torii","year":"2011","journal-title":"Journal of Pharmacological Sciences"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108668_bb0535","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00044011-200626090-00004","article-title":"Efficacy of botulinum toxin type a in the relief of carpal tunnel syndrome","volume":"26","author":"Tsai","year":"2006","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0540","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbi.2013.01.088","article-title":"Botulinum toxin a increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and \u03bc opioid receptor expression in neuropathic mice","volume":"32","author":"Vacca","year":"2013","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0545","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuropharm.2017.03.026","article-title":"A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain","volume":"118","author":"Wang","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.148095","article-title":"Botulinum toxin type a counteracts neuropathic pain by countering the increase of GlyT2 expression in the spinal cord of CCI rats","volume":"1796","author":"Wang","year":"2022","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0555","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neuroscience.2019.10.007","article-title":"SNAP-25 contributes to neuropathic pain by regulation of VGLuT2 expression in rats","volume":"423","author":"Wang","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0560","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.toxicon.2016.11.009","article-title":"Intra-articular injection of botulinum toxin a reduces neurogenic inflammation in CFA-induced arthritic rat model","volume":"126","author":"Wang","year":"2017","journal-title":"Toxicon: Official Journal of the International Society on Toxinology"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0565","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0118-20.2020","article-title":"Ablation of TRPV1+ afferent terminals by capsaicin mediates long-lasting analgesia for trigeminal neuropathic pain","volume":"7","author":"Wang","year":"2020","journal-title":"eNeuro"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0570","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13578-020-00501-4","article-title":"Botulinum toxin type a alleviates neuropathic pain and suppresses inflammatory cytokines release from microglia by targeting TLR2\/MyD88 and SNAP23","volume":"10","author":"Wang","year":"2020","journal-title":"Cell & Bioscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108668_bb0575","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/toxins13100704","article-title":"Peripherally administered botulinum toxin type a localizes bilaterally in trigeminal ganglia of animal model","volume":"13","author":"Waskitho","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_271","article-title":"The history of botulinum toxins in medicine: A thousand year journey","volume":"263","author":"Whitcup","year":"2021","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0585","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00498587","article-title":"125I-labelled botulinum a neurotoxin: Pharmacokinetics in cats after intramuscular injection","volume":"292","author":"Wiegand","year":"1976","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0590","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s40064-016-2071-2","article-title":"Central antinociceptive activity of peripherally applied botulinum toxin type a in lab rat model of trigeminal neuralgia","volume":"5","author":"Wu","year":"2016","journal-title":"SpringerPlus"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108668_bb0595","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0333102412441721","article-title":"Botulinum toxin type a for the treatment of trigeminal neuralgia: Results from a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Wu","year":"2012","journal-title":"Cephalalgia: An International Journal of Headache"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108668_bb0600","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/10749357.2016.1139294","article-title":"Effectiveness of botulinum toxin for lower limbs spasticity after stroke: A systematic review and meta-analysis","volume":"23","author":"Wu","year":"2016","journal-title":"Topics in Stroke Rehabilitation"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108668_bb0605","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1526-4637.2011.01182.x","article-title":"Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats","volume":"12","author":"Xiao","year":"2011","journal-title":"Pain Medicine (Malden, Mass.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0610","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/pme.12017","article-title":"Botulinum toxin type a reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain","volume":"14","author":"Xiao","year":"2013","journal-title":"Pain Medicine (Malden, Mass.)"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108668_bb0615","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","article-title":"Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia","volume":"11","author":"Xiao","year":"2010","journal-title":"Pain Medicine (Malden, Mass.)"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108668_bb0620","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/0022034516659278","article-title":"Antinociceptive effects of botulinum toxin type a on trigeminal neuropathic pain","volume":"95","author":"Yang","year":"2016","journal-title":"Journal of Dental Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108668_bb0625","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-021-00973-8","article-title":"Anthrax toxins regulate pain signaling and can deliver molecular cargoes into ANTXR2+ DRG sensory neurons","volume":"25","author":"Yang","year":"2022","journal-title":"Nature Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0630","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","article-title":"Two doses of botulinum toxin type a for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Zhang","year":"2014","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108668_bb0635","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s10194-017-0793-3","article-title":"Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: A pilot study","volume":"18","author":"Zhang","year":"2017","journal-title":"The Journal of Headache and Pain"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108668_bb0640","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/WNF.0b013e31829cb60e","article-title":"Acute treatment of trigeminal neuralgia with onabotulinum toxin a","volume":"36","author":"Z\u00fa\u00f1iga","year":"2013","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2024.108668_bb0645","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejphar.2016.09.019","article-title":"Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain","volume":"791","author":"Zychowska","year":"2016","journal-title":"European Journal of Pharmacology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T21:28:17Z","timestamp":1717882097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":129,"alternative-id":["S0163725824000883"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108668","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108668"}}